Article Information
History
- August 18, 2020.
Article Versions
- Version 1 (July 23, 2020 - 04:49).
- You are currently viewing Version 2 of this article (August 18, 2020 - 13:42).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Sarah M Lofgren1,*,
- Melanie R Nicol1,
- Ananta S Bangdiwala1,
- Katelyn A Pastick1,
- Elizabeth C Okafor1,
- Caleb P Skipper1,
- Matthew F Pullen1,
- Nicole W Engen1,
- Mahsa Abassi1,
- Darlisha A Williams1,
- Alanna A Nascene1,
- Margaret L Axelrod, BSc2,
- Sylvain A Lother3,
- Lauren J MacKenzie3,
- Glen Drobot3,
- Nicole Marten4,
- Matthew P Cheng6,7,
- Ryan Zarychanski3,4,
- Ilan S Schwartz5,
- Michael Silverman8,
- Zain Chagla9,
- Lauren E Kelly4,
- Emily G McDonald6,7,
- Todd C Lee6,7,
- Kathy H Hullsiek1,
- David R. Boulware1 and
- Radha Rajasingham1,*
- 1University of Minnesota, Minneapolis, Minnesota
- 2Vanderbilt University Medical Center, Nashville, Tennessee
- 3Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba
- 4George & Fay Yee Centre for Healthcare Innovation, Winnipeg, Manitoba
- 5Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta
- 6Research Institute of the McGill University Health Centre, Montreal, Quebec
- 7Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Quebec
- 8Lawson Research Institute, St. Joseph’s Healthcare Center, London, Ontario
- 9McMaster University, Hamilton, Ontario
- ↵* Corresponding author: Dr. Sarah Lofgren, 689 23rd Avenue S.E., Minneapolis, MN 55455; Phone 612-624-4171; Lofg0020{at}umn.edu, Dr. Rajasingham is the Alternative Corresponding Author: radha{at}umn.edu
Posted August 18, 2020.
Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19
